Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); ...
Shares of Celldex rose earlier this week following the presentation of results from a trial with CDX-0159 and 32 healthy patients. A single dose of CDX-1059 suppressed production of plasma tryptase, ...
Celldex Therapeutics (NASDAQ: CLDX) is in a much different place than it was one year ago. The biotech continues to feel the repercussions from the failure of glembatumumab vedotin (glemba) in the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In the last three months, 7 analysts have published ratings on Celldex Therapeutics (NASDAQ:CLDX), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their ...
Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 3:30 pm ET TD Cowen 46th Annual Health Care Conference on Wednesday, March 4 at 9:10 am ET Leerink Global Healthcare ...
It’s not easy to muscle in on a space as competitive as immunology, but Celldex Therapeutics believes that its latest phase 2 win in a chronic form of hives means it has a shot at carving out its own ...
Celldex Therapeutics has some huge competition in immunology, but new phase 2 data from its monoclonal antibody showing a reduction in the severity of a chronic form of hives is helping put the ...
12d
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals
Celldex Therapeutics stock overview Celldex Therapeutics (CLDX) has been drawing investor attention after recent trading left the stock at a last close of US$32. With no single headline event driving ...
Hampton-based Celldex Therapeutics has hired Dr. Margo Heath-Chiozzi as senior vice president, regulatory affairs.Hampton-based Celldex Therapeutics has hired Dr. Margo Heath-Chiozzi as senior vice ...
Celldex Therapeutics (CLDX 1.73%) has two primary goals in 2019. First, the biotech wants to advance its pipeline candidates. Second, it wants to stretch out its cash as much as possible. Celldex did ...
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE)-- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results